Lorlatinib Combinations in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04292119

Recruitment Status : Unknown

Verified January 2021 by Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital.
Recruitment status was: Recruiting

First Posted : March 2, 2020

Last Update Posted : March 10, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Array BioPharma

Pfizer

Information provided by (Responsible Party):

Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	December 1, 2022
Estimated Study Completion Date :	March 1, 2023

To Top